Hims & Hers DOJ Investigation: FDA Scrutiny of Compounded Weight Loss Drugs

Federal authorities are investigating telehealth company Hims & Hers following the company’s announcement of plans to offer a compounded version of a weight loss medication through its platform. The Department of Health and Human Services (HHS) requested the Department of Justice (DOJ) investigation, according to a social media post from HHS general counsel Mike Stuart.

Regulatory Scrutiny of Compounded Drugs

This action follows a statement from the Food and Drug Administration (FDA) indicating it would take “decisive steps” to prevent the widespread marketing of unapproved, compounded versions of GLP-1 drugs. GLP-1 drugs are a class of medications used to treat both obesity and diabetes.

FDA’s Response

The FDA stated its intention to “restrict the use” of ingredients necessary for creating these compounded drugs. This move is designed to “safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.”

Did You Know? The FDA is taking action specifically in response to Hims & Hers’ announcement regarding a plan to widely distribute a compounded weight loss pill.

Expert Insight: The FDA’s intervention highlights the inherent risks associated with compounded medications, which are not subject to the same rigorous review process as FDA-approved drugs. This action underscores the agency’s commitment to ensuring patient safety and product quality within the rapidly evolving telehealth landscape.

Potential Next Steps

The DOJ investigation could lead to a variety of outcomes. It is possible the investigation could result in legal action against Hims & Hers, potentially including injunctions to halt the distribution of the compounded drug. Alternatively, the company could be required to modify its plans to comply with federal regulations. It is also possible the investigation could conclude without formal charges if the DOJ determines no laws were violated.

The FDA’s restriction on ingredients could also impact other companies involved in compounding GLP-1 drugs. Analysts expect this could lead to increased scrutiny of compounding pharmacies and potentially limit access to these medications.

Frequently Asked Questions

What are GLP-1 drugs?

GLP-1 drugs are a category of medications used to treat obesity and diabetes.

What is a compounded drug?

A compounded drug is one that is mixed by a pharmacist, rather than being manufactured by a drug company.

Why is the FDA concerned about compounded versions of GLP-1 drugs?

The FDA is concerned because it cannot verify the quality, safety, or efficacy of drugs that are not FDA-approved.

How might these regulatory actions affect access to weight loss medications for individuals?